These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1166 related items for PubMed ID: 22607530

  • 1. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 6. A pilot study of botulinum toxin A for headache in cervical dystonia.
    Ondo WG, Gollomp S, Galvez-Jimenez N.
    Headache; 2005 Sep; 45(8):1073-7. PubMed ID: 16109123
    [Abstract] [Full Text] [Related]

  • 7. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD, Cullis PA, O'Brien CF, Koller M, Villegas TP, Wallace JD.
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [Abstract] [Full Text] [Related]

  • 8. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
    Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, Dodick DW, Silberstein SD, Diener HC, DeGryse RE, Nolan ME, Turkel CC.
    Neurology; 2011 Oct 11; 77(15):1465-72. PubMed ID: 21956721
    [Abstract] [Full Text] [Related]

  • 9. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 10. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K.
    Curr Med Res Opin; 2005 Mar 15; 21(3):433-8. PubMed ID: 15811212
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
    Poewe W, Burbaud P, Castelnovo G, Jost WH, Ceballos-Baumann AO, Banach M, Potulska-Chromik A, Ferreira JJ, Bihari K, Ehler E, Bares M, Dzyak LA, Belova AN, Pham E, Liu WJ, Picaut P.
    Mov Disord; 2016 Nov 15; 31(11):1649-1657. PubMed ID: 27653448
    [Abstract] [Full Text] [Related]

  • 12. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun 15; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 13. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia.
    Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF, CD 140 Study Group.
    Clin Neuropharmacol; 2012 Jun 15; 35(5):208-14. PubMed ID: 22948497
    [Abstract] [Full Text] [Related]

  • 14. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
    Mathew NT, Jaffri SF.
    Headache; 2009 Jun 15; 49(10):1466-78. PubMed ID: 19912346
    [Abstract] [Full Text] [Related]

  • 15. Botulinum toxin type B for cervical dystonia.
    Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C.
    Cochrane Database Syst Rev; 2005 Jan 25; (1):CD004315. PubMed ID: 15674941
    [Abstract] [Full Text] [Related]

  • 16. A 3-month analysis of disability, quality of life, and disease course in patients with migraine.
    Raggi A, Leonardi M, Bussone G, D'Amico D.
    Headache; 2013 Feb 25; 53(2):297-309. PubMed ID: 23094760
    [Abstract] [Full Text] [Related]

  • 17. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE).
    Jankovic J, Adler CH, Charles D, Comella C, Stacy M, Schwartz M, Manack Adams A, Brin MF.
    J Neurol Sci; 2015 Feb 15; 349(1-2):84-93. PubMed ID: 25595221
    [Abstract] [Full Text] [Related]

  • 18. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
    Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A.
    J Headache Pain; 2018 Feb 05; 19(1):13. PubMed ID: 29404713
    [Abstract] [Full Text] [Related]

  • 19. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects.
    Young W, Shaw J, Bloom M, Gebeline-Myers C.
    Headache; 2008 Feb 05; 48(10):1490-8. PubMed ID: 19076647
    [Abstract] [Full Text] [Related]

  • 20. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, TOPMAT-MIG-201(TOP-CHROME) Study Group.
    Cephalalgia; 2007 Jul 05; 27(7):814-23. PubMed ID: 17441971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.